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descence. None of the treated patients had CDV-related nephro-
toxicity, although one patient had severe renal impairment prior to
CDV therapy (Table1). CDV is a safe and effective therapy for
adenoviral disease in pediatric oncology and BMT patients. We
present a novel algorithm that identiﬁed patients at high-risk for
severe adenoviral disease who would beneﬁt from CDV therapy. In
addition to GVHD, we propose HUS may be associated with
severe adenoviral disease in this popuation.
Table 1.
Risk
Cidofovir
Therapy n
Adenovirus
Clearance N (%)
Adenoviral-
Related
Mortality
N(%)/RR
Overall
Mortality
N(%)
HIGH
14(70%)
Treated 9 8 (89%) 1 (11%)
0.14
3 (33%)
Untreated 5 1 (20%) 4 (80%) 1 5 (100%)
LOW 6
(30%)
Treated 0 N/A N/A N/A
Untreated 6 6 (100%) 1
recrudescence
1 (17%) 1 (17%)
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MORTALITY IN BLOOD AND MARROW TRANSPLANTATION: IS THE
POSTMORTEM A DYING PROCEDURE?
Seftel, M.D.1,2,3, Ho, M.3, Demers, A.2,3, Kawaleski, S.1,2,
Bow, E.J.1,2,3, Rubinger, M.1,2,3, Schacter, B.1,2,3, Woloschuk, D.1,3,
Bredeson, C.1,3 1. Manitoba Blood and Marrow Transplant Program,
Winnipeg, MB, Canada; 2. CancerCare Manitoba, Winnipeg, MB,
Canada; 3. University of Manitoba, Winnipeg, MB, Canada.
Introduction: Little is known about post-mortem (PM) char-
acteristics in blood and marrow transplantation (BMT), includ-
ing the variables that predict the decision to perform the PM,
and whether meaningful information is obtained from the PM.
We performed a comprehensive analysis of PMs performed at
our center in order to determine PM rates, temporal trends, and
the utility of this investigation. Methods: All deceased patients
since the BMT program inception in 1990 until 2004 were
analyzed by computerized database and chart review. Patients
(pts) undergoing PM were compared to non-PM deceased pts.
PM reports were graded as to whether they showed major,
minor, or no disagreement with the ante-mortem diagnoses. PM
rates were compared to those of the general hospital population.
Results: Of the 476 pts undergoing myeloablative BMT, 225
died and 48 (27%) underwent PM, of which 41(85%) were full
and 7(15%) limited. The 48 PM pts had a median age of 44 years
(range) (18–63) and only 11 (23%) were post autologous BMT.
Forty-four PM pts (92%) died either on the transplant ward or
the ICU. The performance of a PM was more likely in pts dying
100 days post BMT (P  .001), with acute GVHD (P  .03),
in the ICU (P  .001), and after allografting (P  .001). PM
rates declined signiﬁcantly between the periods 1990–1994,
1995–1999, and 2000–2004 (P  .001). PM was more likely if
death occurred outside of ofﬁce hours (P  .02). The PM rate
at the general hospital was 21%, and showed a similar downward
temporal trend. Major, minor, and no disagreements at PM
were present in 22 (46%), 8(17%), and 18 (37%) of cases.
Conclusions: Despite 46% major disagreement between ante-
and postmortem diagnoses, rates for this procedure are falling in
concert with an overall reduction of PM in hospitalized pts.
Deaths occuring after 100 days post BMT and those outside of
a high care setting are less likely to undergo PM. As BMT pts
remain complex and liable to an extensive array of treatment and
disease-related complications, it is recommended that the PM
regains its role as a valuable investigation. This is especially
relevant in era of older and more inﬁrm pts undergoing non-
myeloablative BMT.
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VALGANCICLOVIR IS EFFECTIVE IN THE PREEMPTIVE TREATMENT OF
CYTOMEGALOVIRUS (CMV) INFECTION AFTER ALLOGENEIC STEM
CELL TRANSPLANT (ASCT)
Aberle, M.F.2, Bachier, C.1, Lemaistre, F.C.1, Shaughnessy, P.J.1 1.
Texas Transplant Institute, San Antonio, TX; 2. Methodist Hospital
System, San Antonio, TX.
Background: CMV infection can cause life-threatening compli-
cations in allogeneic stem cell transplant patients. Preemptive
treatment with ganciclovir is effective for patients with CMV
infection following ASCT. Valganciclovir is a valine esther of
ganciclovir with improved bioavailability. Methods: A retrospec-
tive analysis of ASCT patients receiving preemptive therapy with
ganciclovir or valganciclovir for treatment of CMV infection.
CMV infection was deﬁned as a titer of greater than 5 pg/ul using
the digene hybrid capture CMV-DNA assay. Results: A total of
144 patients received ASCT between January of 2001 and Septem-
ber of 2005. Of these, 39 received preemptive treatment with
valganciclovir (21), ganciclovir (13), or a combination of both
drugs (5). A total of 13 patients received preemptive therapy with
ganciclovir. All 13 patients were seropositive for CMV. Donor
source was: bone marrow (bm)  3, peripheral blood (pb)  10,
match unrelated donors (mud)  3, matched related sibling
(mrs)  10. Conditioning regimens included: reduced intensity
(rit)  5, ablative  8. Thirteen of thirteen patients were on
steroids for treatment of graft-versus-host disease (GVHD). Pa-
tients developed CMV infection on days 4 to 349 (median 
46) after ASCT. The peak CMV-DNA titer was 5.7 to 288 pg/ul
(median 48.65 pg/ul). Twelve of thirteen patients responded to
treatment. The time to response to treatment occurred 5 to 28 days
(median 13) after initiation of ganciclovir. One patient died from
interstitial pneumonitis related to CMV. Six patients received
maintenance therapy with valganciclovir and 3 patient developed
reactivation of their CMV viremia 69–84 days after their ﬁrst
infection.
A total 21 patients received preemptive treatment with valganci-
clovir. Donor source was pb  15, bm 6; mud  14, mrs  7 .
Nineteen patients were seropositive for CMV (2 seronegative pa-
tients with seropositive donor). Conditioning regimens included:
rit  6, ablative  15. Eighteen of twenty-one patients were on
steroids for treatment of GVHD. Patients developed CMV infec-
tion on days 11 to 700 (median  32 after ASCT). The peak
CMV-DNA titer was 2.1 to 149.3 pg/ul (median  26 pg/ul).
Twenty-one of twenty-one patients responded to preemptive ther-
apy with valganciclovir. The time to response to treatment oc-
curred 3 to 34 days (median  10) after initiation of valganciclovir.
Four patients developed CMV reactivation at 88–127 days after
the ﬁrst infection. Conclusions: Valganciclovir is comparable to
ganciclovir for the treatment of CMV infection.
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ALTERNATE DAY GANCICLOVIR AND FOSCARNET IS SAFE AND EFFEC-
TIVE IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTIONS IN AT-
RISK PEDIATRIC AND ADOLESCENT ALLOGENEIC STEM CELL TRANS-
PLANT RECIPIENTS
Shereck, E.1, Militano, O.2, Cooney, E.1, van de Ven, C.1,
Cheung, Y.K.K.3, Del Toro, G.1, Bradley, B.1, George, D.1, Garvin, J.1,
Hawks, R.1, Wischover, C.1, Wolownick, K.1, Schwartz, J.4,
Della-Lotta, P.4, Cairo, M.S.1,4,5 1. Department of Pediatrics; 2. De-
partment of Pharmacy; 3. Division of Biostatistics; 4. Deptartment of
Pathology; 5. Deptartment of Medicine, Morgan Stanley Children’s
Hospital of NewYork-Presbyterian, Columbia University, New York,
NY.
CMV prophylaxis with ganciclovir (Gan) post AlloSCT reduces
the incidence of CMV disease to 3%, but is associated with a
30% incidence of grade III/IV hematologic toxicity (Goodrich et al
NEJM. 1991). Foscarnet (Fos) is effective against CMV, but has
dose limiting renal toxicity (Deray et al Am J nephrol. 1989).
Combination Gan/Fos is more effective than monotherapy in
CMV retinitis in HIV patients (Peters et al J Inf Dis.1994). We
evaluated the safety and efﬁcacy of alternate day Gan (5 mg/kg/
48H)/Fos (90 mg/kg/48H) in 50 pediatric AlloSCT recipients
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undergoing 54 AlloSCTs where donors and/or recipients were
CMV seropositive. CMV seronegative donors and recipient pairs
received leukodepleted blood products only. Prophylaxis spanned
frommyeloid recovery (ANC 750/mm3) until day100. Patients
were: M:F 29:21; mean age 8 years (0.8–20 years); donor sources:
24 HLA matched related bone marrow (BM) or peripheral blood
stem cells (PBSC), 2 related cord blood (CB), 3 MUDs, and 25
unrelated CB. HLA matching for related PBSC/BM included
twenty 6/6 and four 5/6; related CB included one 6/6 and one 5/6;
unrelated adult donors included one 10/10 and two 9/10; unrelated
CBT included two 6/6, eight 5/6 and ﬁfteen 4/6. Twenty one
(39%) patients received full intensity conditioning and 33 (61%)
patients received reduced intensity conditioning. GVHD prophy-
laxis included tacrolimus/mycophenolate mofetil as we have pre-
viously described (Osunkwo/Cairo BBMT. 2004). Mean nucleated
and CD34 cell counts were 8.1  4.9  108/kg and 5.4  2.4 
106/kg, respectively, for BM/PBSC; 4.7  2.7  107/kg and 2.6 
2.0  105/kg, respectively, for CB. Despite a 39% probability of
grade II-IV acute GVHD, no patient developed systemic CMV
disease. Twenty eight percent had grade III/IV hematological
toxicity possibly secondary to Gan/Fos. Patients developed tran-
sient nephrotoxicity and electrolyte imbalances secondary to Gan/
Fos, however no patient developed permanent renal dysfunction
and all patients were on at least 2 other concomitant nephrotoxic
drugs. Probability of 1-year overall survival was 69%. Alternate day
Gan/Fos in AlloSCT recipients where recipient and/or donor is
seropositive, especially in unrelated donor recipients, appears to be
tolerable and effective in preventing CMV systemic disease. A
future randomized trial will be required to determine if this ap-
proach not only reduces systemic CMV disease but also reduces
hematological toxicity of daily ganciclovir.
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EFFICACY OF POSACONAZOLE (POS) VS STANDARD THERAPY AND
SAFETY OF POS IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
RECIPIENTS VS OTHER PATIENTS WITH ASPERGILLOSIS
van Burik, J.-A.1, Perfect, J.2, Louie, A.3, Graybill, J.R.4,
Pedicone, L.5, Raad, I.I.6 1. University of Minnesota, Minneapolis, MN;
2. Duke University Medical Center, Durham, NC; 3. Ordway Research
Institute, Albany, NY; 4. University of Texas Health Sciences Center,
San Antonio, TX; 5. Schering-Plough Research Institute, Kenilworth,
NJ; 6. M.D. Anderson Cancer Center, Houston, TX.
Introduction: Antifungal therapy response is typically low in
HSCT recipients with aspergillosis. We compared (1) outcomes in
POS-treated HSCT and non-HSCT recipients with aspergillosis
with those of external controls receiving other antifungal therapy; (2)
safety of POS in HSCT and non-HSCT recipients with aspergillosis.
Methods: Patients with invasive fungal infections, including HSCT
recipients, who were intolerant of or refractory to other antifungal
therapy received oral POS 800 mg/d in divided doses in a prospective,
open-label, multicenter study. An external control group mainly in-
cluded patients concurrently hospitalized at the same institutions with
similar baseline characteristics receiving other therapy (amphotericin
B [any formulation], itraconazole, and/or investigational agents when
the study was conducted [eg, voriconazole and echinocandins]) as
salvage treatment. A blinded data review committee assessed eligibil-
ity, diagnosis, and outcome of all patients. Results: One hundred
seven of 330 patients in the POS group and 86 of 279 in the control
group had aspergillosis. Overall response was 42% (45/107) in the
POS group and 26% (22/86) in the control group (P .006; OR 4.06
[95% CI 1.5–11.04]). POS was associated with signiﬁcant survival
beneﬁt vs other therapy (P  .0003). In patients with neutropenia at
baseline (500/l), POS was associated with 24% response vs 8% in
controls. Percentage of responders was lower in HSCT recipients
than in the overall populations of both groups but was greater in
POS-treated vs control HSCT recipients. Response in POS-treated
autologous HSCT recipients was higher than in controls (Table 1) .
Response in HSCT recipients by type of leukemia is shown in the
Table. Most common adverse events (AEs) related to POS were
nausea (HSCT 11%; non-HSCT 13%), vomiting (HSCT 4%; non-
HSCT 6%), and rash (HSCT 2%; non-HSCT 6%). Convulsions
(n  2) and increased hepatic enzymes (n  2) were serious AEs in
HSCT recipients considered by the investigator to be at least possibly
related to POS. POS was well tolerated. Conclusions: There was a
signiﬁcantly greater global response rate and survival advantage in
POS-treated patients with aspergillosis vs external controls receiving
other antifungal therapy. In HSCT recipients, there was a greater
response rate in the POS group vs the control group, suggesting POS
as an option for HSCT recipients with fungal infections refractory to
other therapy. Safety of POS was similar in HSCT and non-HSCT
recipients (Table1).
Table 1.
POS External Control
Total,
n
Responders,
n (%)
Total,
n
Responders,
n (%)
HSCT status
Any HSCT 55 21 (38.2) 38 7 (18.4)
Allogeneic 48 15 (31.3) 34 7 (20.6)
Autologous 7 6 (85.7) 4 0 (0)
Type of
leukemia
Acute
myelogenous 14 5 (36) 5 1 (20)
Acute
lymphocytic 5 1 (20) 6 3 (50)
Chronic
myelogenous 9 6 (67) 7 0 (0)
Chronic
lymphocytic 4 0 (0) 2 1 (50)
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URSODIOL PROPHYLAXIS AGAINST HEPATIC VENO-OCCLUSIVE DIS-
EASE IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Zirakzadeh, A.1, Montori, V.1, Imran, H.1, Litzow, M.1, Kumar, S.1
Mayo College of Medicine, Rochester, MN.
Hepatic veno-occlusive disease (VOD) is a well-recognized compli-
cation of hematopoietic stem cell transplantation (HSCT). Ursodiol
has been studied as a prophylactic agent against this condition with
varying success. We performed a systematic review and meta-analysis
of the existing literature to assess the effectiveness of ursodiol in
preventing VOD in patients undergoingHSCT.We conducted com-
puterized and hand searches of ursodiol, hepatic VOD, and variations
of the two terms. We then selected those randomized trials and
observational studies which compared the incidence of VOD in
HSCT patients receiving ursodiol versus control. The outcome data
from the eligible studies were pooled and summarized (Table 1). We
also preformed an a priori subgroup analysis based on study type
(observational vs randomized clinical trial), type of conditioning reg-
imen used (busulfan vs total body irradiation based), time from urso-
diol initiation to transplant, type of transplant (allogeneic vs autolo-
gous) and different diagnostic criteria for VOD (Seattle criteria vs
modiﬁed Seattle criteria. Overall, we found that ursodiol prophylaxis
decreased the risk of VOD (pooled OR 0.33, 95% CI 0.12, 0.90). All
subgroups showed beneﬁted from ursodiol use; however wide conﬁ-
dence intervals indicate imprecision in the estimate of this beneﬁt.
Also, there was no statistically signiﬁcant difference in survival when
comparing subgroups: clinical trial versus observational study, P 
.89; busulfan vs total body irradiation, P .64; Seattle versus modiﬁed
Seattle criteria, P .36.Wewere unable to perform statistical analysis
on the type of transplant (allogeneic vs autologous), and time from
ursodiol initiation to transplant. Finally, despite our a priori subgroup
analysis, unexplained differences in results (ie, heterogeneity) contin-
ued to exist between studies. These differences were only partially
explained by analysis based on diagnostic criteria. I2 (the test statistic
used to describe heterogeneity) decreased to 0% for the modiﬁed
Seattle criteria group but remained high (76%) for the Seattle criteria
group. This review supports the assertion that ursodiol decreases the
incidence of VOD in patients receiving HSCT. However, unex-
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